Healthy
Conditions
Keywords
Healthy adults, Phase I
Brief summary
Primary: To compare the pharmacodynamic efficacy of PN 200 in controlling intragastric pH (percent time pH\> 4.0) following twice daily administration at different dosing times relative to food (30 or 60 minutes prior to food or taken togeterh with food) on Day 5.
Detailed description
This study is designed to evaluate the effect of different dosing times of PN 200 relative to food on the intragastric pH profile of PN 200. PN 200 contains immediate release omeprazole, which may be subject to acid degradation in the stomach. Food is known to have a buffering effect on acid and therefore may result in less degradation of immediate release omeprazole. Alternatively, food may decrease the absorption of omeprazole in the duodenum. The relative magnitude of these effects is unknown. The data from this study will aid in choosing the optimal timing of PN dosing relative to food in future studies. The study is not blinded because the primary endpoint (intragastric pH) is a physiological variable not believed to be readily influenced by conscious or subconscious subject control.
Interventions
DRUGPN 200
Sponsors
POZEN
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Male or non-lactating, non-pregnant female subjects who are 18-55 years of age 2. Female subjects are eligible for participation in the study if they are of: * Non-childbearing potential (i.e., physiologically incapable of becoming pregnant); or, * Childbearing potential, have a negative pregnancy test (urine) at screening, and at least one of the following applies or is agreed to by the subject: * Female sterilization or sterilization of male partner; or, * Hormonal contraception by oral route, implant, injectable, vaginal ring; or, * Any intrauterine device (IUD) with published data showing that the lowest expected failure rate is less than 1% per year; * Double barrier method (2 physical barriers or 1 physical barrier plus spermicide); or * Any other method with published data showing that the lowest expected failure rate is less than 1% per year 3. Physical examination findings within normal limits for age 4. Able to understand and comply with study procedures required and able and willing to provide written informed consent prior to any study procedures being performed
Exclusion criteria
1. History of hypersensitivity, allergy or intolerance to omeprazole or other proton-pump inhibitors 2. History of hypersensitivity, allergy or intolerance to any NSAID (including aspirin) and/or a history of NSAID-induced symptoms of asthma, rhinitis, and/or nasal polyps 3. History of peptic ulcer disease or other acid related gastrointestinal symptoms 4. Participation in any study of an investigational treatment in the 4 weeks before screening or participation in another study at any time during the period of this study 5. Any significant medical illness that would contraindicate participation in the study 6. Gastrointestinal disorder or surgery leading to impaired drug absorption 7. Any significant mental illness, such as schizophrenia or bipolar disorder 8. Cardio- or cerebrovascular disease, based on history or risk factors, or clinically significant ECG in the investigator's opinion 9. Personal or family history of an inherited or acquired bleeding disorder 10. Positive test result for H pylori at screening
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the pharmacodynamic efficacy of PN 200 in controlling intragastric pH (percent time pH > 4.0) | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the effect of different dosing times of PN 200 on the pharmacokinetic properties of omeprazole | — |
Countries
United States
Outcome results
None listed